Literature DB >> 7333324

On the distribution and elimination of haloperidol in cholecystectomized patients.

A Forsman, M Larsson, H Lundborg, P Renstrom.   

Abstract

A single oral dose of haloperidol was given to 19 patients prior to cholecystectomy. The concentration of haloperidol was assessed in serum, urine, fatty tissue, liver tissue, choledochal bile and bile bladder contents. The biological half-life of the drug in the serum was 25.1 +/- 12.9 hours, which is comparable to that in healthy volunteers. Only minute amounts of the drug were excreted with the urine. The drug concentration was only slightly elevated in choledochal bile but in the bile bladder contents it was about 11 times higher than that in the serum. The low concentration of haloperidol in the bile indicated that there was no substantial enterohepatic recirculation of the drug in this patient material. The concentration of haloperidol in fatty tissue was about 20 times, and in liver tissue 900 times higher than that in the serum. The corresponding figures for intramuscular administration of haloperidol were 10 and 325, respectively. A possible relationship between the side-effects and the route of administration is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7333324     DOI: 10.1007/BF03189521

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  5 in total

1.  Neurolept-analgesia--an alternative to general anaesthesia.

Authors:  E NILSSON; P JANSSEN
Journal:  Acta Anaesthesiol Scand       Date:  1961       Impact factor: 2.105

2.  Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain.

Authors:  R Ohman; M Larsson; I M Nilsson; J Engel; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-09       Impact factor: 3.000

3.  A gas chromatographic method for determining haloperidol. A sensitive procedure for studying serum concentration and pharmacokinetics of haloperidol in patients.

Authors:  A Forsman; E Mårtensson; G Nyberg; R Ohman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

4.  Pharmacokinetic studies on haloperidol in man.

Authors:  A Forsman; R Ohman
Journal:  Curr Ther Res Clin Exp       Date:  1976-09

5.  Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.

Authors:  R T Rubin; A Forsman; J Heykants; R Ohman; B Tower; M Michiels
Journal:  Arch Gen Psychiatry       Date:  1980-09
  5 in total
  4 in total

1.  Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.

Authors:  D W Eyles; H A Whiteford; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs.

Authors:  Guillermo Gervasini; Maria J Caballero; Juan A Carrillo; Julio Benitez
Journal:  ISRN Pharmacol       Date:  2013-02-13

3.  Evaluating the effects and safety of intravenous lipid emulsion on haloperidol-induced neurotoxicity in rabbit.

Authors:  Mohammad Moshiri; Amir Hooshang Mohammadpour; Maryam Vahabzadeh; Leila Etemad; Bahram Memar; Hossein Hosseinzadeh
Journal:  Biomed Res Int       Date:  2014-05-29       Impact factor: 3.411

4.  In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.

Authors:  Jacek Wójcikowski; Przemysław J Danek; Agnieszka Basińska-Ziobroń; Renata Pukło; Władysława A Daniel
Journal:  Pharmacol Rep       Date:  2020-03-26       Impact factor: 3.024

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.